The Committee will hear from representatives of the Human Tissue Authority, the Human Fertilisation and Embryology Authority, the Health Research Authority and others on Tuesday 8 January.

The Committee will ask the witnesses for their response to evidence they have received that the regulatory process for regenerative medicine in the UK is too complex, what is being done to harmonise regulation across Europe and internationally, and what efforts they are making to facilitate early dialogue with companies developing regenerative therapies.